- Home
- APLS vs DNLI Comparison
APLS vs DNLI Comparison
Compare APLS & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLS
- DNLI
- Stock Information
- Founded
- APLS 2009
- DNLI 2013
- Country
- APLS United States
- DNLI United States
- Employees
- APLS N/A
- DNLI N/A
- Industry
- APLS Biotechnology: Pharmaceutical Preparations
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APLS Health Care
- DNLI Health Care
- Exchange
- APLS Nasdaq
- DNLI Nasdaq
- Market Cap
- APLS 3.6B
- DNLI 3.1B
- IPO Year
- APLS 2017
- DNLI 2017
- Fundamental
- Price
- APLS $27.52
- DNLI $20.73
- Analyst Decision
- APLS Buy
- DNLI Strong Buy
- Analyst Count
- APLS 18
- DNLI 13
- Target Price
- APLS $46.71
- DNLI $37.91
- AVG Volume (30 Days)
- APLS 1.4M
- DNLI 814.8K
- Earning Date
- APLS 02-28-2025
- DNLI 03-04-2025
- Dividend Yield
- APLS N/A
- DNLI N/A
- EPS Growth
- APLS N/A
- DNLI N/A
- EPS
- APLS N/A
- DNLI N/A
- Revenue
- APLS $715,216,000.00
- DNLI N/A
- Revenue This Year
- APLS $97.25
- DNLI N/A
- Revenue Next Year
- APLS $12.68
- DNLI $289.18
- P/E Ratio
- APLS N/A
- DNLI N/A
- Revenue Growth
- APLS 162.10
- DNLI 204.74
- 52 Week Low
- APLS $24.34
- DNLI $14.56
- 52 Week High
- APLS $71.90
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- APLS 38.99
- DNLI 42.56
- Support Level
- APLS $26.84
- DNLI $21.33
- Resistance Level
- APLS $28.59
- DNLI $22.81
- Average True Range (ATR)
- APLS 1.12
- DNLI 1.27
- MACD
- APLS -0.03
- DNLI -0.10
- Stochastic Oscillator
- APLS 18.09
- DNLI 15.83
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.